Akebia Therapeutics, Inc. (AKBA) 10-Year Financial Performance & Capital Metrics

AKBA • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $160M -17.7%
EBITDA -$13M -50.3%
Net Income -$69M -33.7%
EPS (Diluted) -0.33 -17.9%
Gross Margin 60.56% -2.2%
EBITDA Margin -8.1% -82.6%
Operating Margin -31.51% -32.6%
Net Margin -43.33% -62.4%
ROE -
ROIC -63.97% +58.3%
Debt/Equity -
Interest Coverage -2.78 +63.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Sales declining 13.7% over 5 years
✗Shares diluted 12.5% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-13.72%

3Y-8.87%

TTM32.49%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM65.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM67.67%

ROCE

10Y Avg-50.01%

5Y Avg-48.13%

3Y Avg-31.2%

Latest-35.85%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	1.53M	177.98M	207.74M	335M	294.64M	211.65M	292.48M	194.62M	160.18M
Revenue Growth %	-	-	114.95%	0.17%	0.61%	-0.12%	-0.28%	0.38%	-0.33%	-0.18%
Cost of Goods Sold+	96K	115.78M	617K	7.68M	145.34M	63.96M	81.49M	22.5M	74.15M	63.18M
COGS % of Revenue	-	75.43%	0%	0.04%	0.43%	0.22%	0.39%	0.08%	0.38%	0.39%
Gross Profit+	-96K	-114.25M	177.37M	200.06M	189.66M	230.68M	130.16M	269.99M	120.47M	97M
Gross Margin %	-	-74.43%	1%	0.96%	0.57%	0.78%	0.61%	0.92%	0.62%	0.61%
Gross Profit Growth %	1%	-1189.1%	2.55%	0.13%	-0.05%	0.22%	-0.44%	1.07%	-0.55%	-0.19%
Operating Expenses+	61.51M	138M	257.9M	378.2M	475.95M	608.51M	394.66M	350.77M	166.73M	147.47M
OpEx % of Revenue	-	89.9%	1.45%	1.82%	1.42%	2.07%	1.86%	1.2%	0.86%	0.92%
Selling, General & Admin	18.5M	22.21M	27.01M	87.06M	149.46M	154.1M	174.14M	138.6M	100.23M	106.55M
SG&A % of Revenue	-	14.47%	0.15%	0.42%	0.45%	0.52%	0.82%	0.47%	0.52%	0.67%
Research & Development	43.02M	115.78M	230.89M	291.07M	322.97M	218.49M	147.85M	165.99M	63.08M	37.65M
R&D % of Revenue	-	75.43%	1.3%	1.4%	0.96%	0.74%	0.7%	0.57%	0.32%	0.24%
Other Operating Expenses	287K	-188K	204K	0	3.53M	235.92M	72.67M	46.18M	3.42M	3.28M
Operating Income+	-61.51M	-136.46M	-79.92M	-178.14M	-286.29M	-377.83M	-264.5M	-80.78M	-46.26M	-50.47M
Operating Margin %	-	-88.9%	-0.45%	-0.86%	-0.85%	-1.28%	-1.25%	-0.28%	-0.24%	-0.32%
Operating Income Growth %	-0.62%	-1.22%	0.41%	-1.23%	-0.61%	-0.32%	0.3%	0.69%	0.43%	-0.09%
EBITDA+	-61.42M	-136.16M	-79.3M	-175.72M	-249.87M	-343.13M	-226.53M	-43.08M	-8.63M	-12.97M
EBITDA Margin %	-	-88.71%	-0.45%	-0.85%	-0.75%	-1.16%	-1.07%	-0.15%	-0.04%	-0.08%
EBITDA Growth %	-0.62%	-1.22%	0.42%	-1.22%	-0.42%	-0.37%	0.34%	0.81%	0.8%	-0.5%
D&A (Non-Cash Add-back)	96K	296K	617K	2.42M	36.42M	34.69M	37.97M	37.7M	37.63M	37.5M
EBIT	-61.51M	-136.46M	-76.67M	-178.16M	-286.29M	-174.52M	-227.88M	-34.64M	-45.89M	-51.23M
Net Interest Income+	0	901K	2.8M	6.15M	792K	-8.87M	-19.94M	-15.69M	-6.03M	-18.18M
Interest Income	0	901K	2.8M	6.15M	2.19M	0	0	0	0	0
Interest Expense	510K	0	0	0	1.4M	8.87M	19.94M	15.69M	6.03M	18.18M
Other Income/Expense	497K	713K	3M	6.24M	-2K	-7.01M	-17.52M	-13.45M	-5.67M	-18.94M
Pretax Income+	-60.72M	-135.75M	-76.91M	-171.9M	-286.29M	-384.84M	-282.02M	-94.23M	-51.92M	-69.41M
Pretax Margin %	-	-88.43%	-0.43%	-0.83%	-0.85%	-1.31%	-1.33%	-0.32%	-0.27%	-0.43%
Income Tax+	-510K	-901K	-2.8M	-28.34M	-6.63M	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.98%	1%	1%	1%	1%	1%
Net Income+	-60.72M	-135.75M	-76.91M	-171.9M	-279.66M	-384.84M	-282.02M	-94.23M	-51.92M	-69.41M
Net Margin %	-	-88.43%	-0.43%	-0.83%	-0.83%	-1.31%	-1.33%	-0.32%	-0.27%	-0.43%
Net Income Growth %	-0.64%	-1.24%	0.43%	-1.24%	-0.63%	-0.38%	0.27%	0.67%	0.45%	-0.34%
Net Income (Continuing)	-60.72M	-135.75M	-73.67M	-143.59M	-279.66M	-384.84M	-282.02M	-94.23M	-51.92M	-69.41M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.29	-3.60	-1.77	-1.47	-2.36	-2.53	-1.48	-0.58	-0.28	-0.33
EPS Growth %	0.05%	-0.57%	0.51%	0.17%	-0.61%	-0.07%	0.42%	0.61%	0.52%	-0.18%
EPS (Basic)	-2.29	-3.60	-1.77	-1.47	-2.36	-2.53	-1.48	-0.58	-0.28	-0.33
Diluted Shares Outstanding	26.47M	37.72M	43.5M	116.89M	118.4M	138.46M	165.95M	182.78M	187.47M	210.95M
Basic Shares Outstanding	26.47M	37.72M	43.5M	116.89M	118.4M	138.46M	165.95M	182.78M	187.47M	210.95M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	141.02M	296.32M	358.36M	468.27M	309.53M	371.44M	271.15M	185.18M	118.15M	113.83M
Cash & Short-Term Investments	138.45M	260.34M	317.79M	321.64M	147.96M	269.08M	149.8M	90.47M	42.92M	51.87M
Cash Only	49.78M	187.34M	70.16M	104.64M	147.71M	229.09M	149.8M	90.47M	42.92M	51.87M
Short-Term Investments	88.68M	73.01M	247.64M	217M	245K	39.99M	0	0	0	0
Accounts Receivable	0	33.82M	34.22M	16.67M	38.86M	28.57M	51.58M	40.28M	39.29M	34.37M
Days Sales Outstanding	-	8.04K	70.17	29.28	42.34	35.4	88.95	50.27	73.69	78.31
Inventory	0	0	0	114.25M	116.35M	61.02M	36.63M	21.57M	15.69M	16.24M
Days Inventory Outstanding	-	-	-	5.43K	292.2	348.19	164.05	349.94	77.24	93.84
Other Current Assets	2.56M	0	6.35M	15.72M	6.36M	12.76M	0	32.86M	20.24M	7.32M
Total Non-Current Assets+	1.92M	3.9M	5.89M	528.26M	461.67M	272.7M	258.2M	170.87M	123.55M	106.84M
Property, Plant & Equipment	540K	2.61M	3.62M	8.02M	39.42M	35.5M	40.61M	34.37M	16.05M	10.42M
Fixed Asset Turnover	-	0.59x	49.21x	25.89x	8.50x	8.30x	5.21x	8.51x	12.13x	15.38x
Goodwill	0	0	0	55.05M	55.05M	55.05M	59.04M	59.04M	59.04M	59.04M
Intangible Assets	0	0	0	328.15M	291.21M	144.17M	108.13M	72.08M	36.04M	0
Long-Term Investments	0	0	1.28M	2.46M	2.09M	2.04M	0	0	0	0
Other Non-Current Assets	1.38M	1.28M	2.27M	21.8M	73.89M	35.94M	50.42M	5.37M	12.42M	37.38M
Total Assets+	142.94M	300.22M	364.25M	996.54M	771.2M	644.14M	529.35M	356.05M	241.7M	220.67M
Asset Turnover	-	0.01x	0.49x	0.21x	0.43x	0.46x	0.40x	0.82x	0.81x	0.73x
Asset Growth %	0.29%	1.1%	0.21%	1.74%	-0.23%	-0.16%	-0.18%	-0.33%	-0.32%	-0.09%
Total Current Liabilities+	11.87M	114.27M	144.35M	265.69M	208.12M	187.15M	261.05M	129.54M	99.87M	80.91M
Accounts Payable	2.31M	2.04M	7M	42.8M	39.22M	41.31M	33.59M	18.02M	14.63M	15.18M
Days Payables Outstanding	8.79K	6.43	4.14K	2.03K	98.49	235.72	150.44	292.39	72.04	87.7
Short-Term Debt	0	0	0	15M	4.99M	5.29M	97.54M	32M	19.55M	4.31M
Deferred Revenue (Current)	-8K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0	0
Other Current Liabilities	6.55M	29K	46.47M	26.82M	80.93M	72.89M	31.18M	52.53M	18.26M	22.75M
Current Ratio	11.88x	2.59x	2.48x	1.76x	1.49x	1.98x	1.04x	1.43x	1.18x	1.41x
Quick Ratio	11.88x	2.59x	2.48x	1.33x	0.93x	1.66x	0.90x	1.26x	1.03x	1.21x
Cash Conversion Cycle	-	-	-	3.42K	236.06	147.87	102.57	107.82	78.88	84.46
Total Non-Current Liabilities+	74K	117.83M	100.57M	94.92M	168.33M	209.38M	194.29M	221.29M	172.42M	188.94M
Long-Term Debt	0	0	0	0	75.81M	96.38M	0	34.08M	71.2M	175.47M
Capital Lease Obligations	0	0	0	0	27.53M	24.62M	33.7M	28.96M	8.95M	3.55M
Deferred Tax Liabilities	0	0	181K	6.63M	0	0	0	0	0	0
Other Non-Current Liabilities	74K	2.51M	2.61M	32.58M	31.87M	63.03M	139.11M	114.95M	48.98M	9.93M
Total Liabilities	11.94M	232.1M	244.92M	360.61M	376.44M	396.52M	455.34M	350.82M	272.29M	269.86M
Total Debt+	14K	0	0	15M	108.32M	126.28M	136.05M	99.78M	104.18M	188.73M
Net Debt	-49.76M	-187.34M	-70.16M	-89.64M	-39.39M	-102.81M	-13.75M	9.32M	61.26M	136.86M
Debt / Equity	0.00x	-	-	0.02x	0.27x	0.51x	1.84x	19.08x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-120.61x	-	-	-	-204.49x	-42.59x	-13.27x	-5.15x	-7.67x	-2.78x
Total Equity+	131M	68.12M	119.33M	635.93M	394.76M	247.62M	74.01M	5.23M	-30.58M	-49.19M
Equity Growth %	0.26%	-0.48%	0.75%	4.33%	-0.38%	-0.37%	-0.7%	-0.93%	-6.85%	-0.61%
Book Value per Share	4.95	1.81	2.74	5.44	3.33	1.79	0.45	0.03	-0.16	-0.23
Total Shareholders' Equity	131M	68.12M	119.33M	635.93M	394.76M	247.62M	74.01M	5.23M	-30.58M	-49.19M
Common Stock	0	0	0	1K	1K	1K	1K	2K	2K	2K
Retained Earnings	-161.39M	-297.14M	-374.05M	-514.39M	-794.05M	-1.18B	-1.46B	-1.56B	-1.61B	-1.68B
Treasury Stock	-162K	0	0	0	0	0	0	0	0	0
Accumulated OCI	-234K	-42K	-442K	-261K	0	13K	6K	6K	6K	6K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-52.41M	57.91M	-56.16M	-97.49M	-257.44M	-110.39M	-252.97M	-73.15M	-23.38M	-40.66M
Operating CF Margin %	-	37.72%	-0.32%	-0.47%	-0.77%	-0.37%	-1.2%	-0.25%	-0.12%	-0.25%
Operating CF Growth %	-0.91%	2.1%	-1.97%	-0.74%	-1.64%	0.57%	-1.29%	0.71%	0.68%	-0.74%
Net Income	-60.72M	-135.75M	-76.91M	-143.59M	-279.66M	-383.46M	-282.02M	-92.56M	-51.92M	-69.41M
Depreciation & Amortization	96K	296K	617K	2.42M	38.65M	33.59M	36.13M	37.7M	41.85M	37.5M
Stock-Based Compensation	4.71M	5.83M	8.87M	19.04M	11.93M	24.46M	0	17.85M	9.32M	7.78M
Deferred Taxes	0	0	0	-28.34M	-6.63M	204.08M	0	0	0	0
Other Non-Cash Items	558K	800K	4.02M	16.95M	77.35M	24.61M	98.54M	-34.7M	-1.9M	23.15M
Working Capital Changes	2.94M	186.73M	7.25M	36.02M	-99.07M	-13.67M	-105.61M	-1.44M	-20.73M	-39.68M
Change in Receivables	0	-33.82M	-393K	33.38M	-22.2M	12.01M	-24.03M	11.7M	994K	4.05M
Change in Inventory	0	0	16.79M	26K	-29.14M	6.16M	-24.95M	19.79M	-2.54M	-28.4M
Change in Payables	231K	-274K	4.96M	13.72M	1.37M	3.68M	-11.73M	1.5M	-5.24M	-1.36M
Cash from Investing+	-13.69M	12.71M	-177.26M	36.59M	211.18M	-40M	39.94M	-114K	0	-33K
Capital Expenditures	-414K	-2.66M	-1.62M	-1.61M	-6.66M	-317K	-59K	-114K	0	-33K
CapEx % of Revenue	-	1.73%	0.01%	0.01%	0.02%	0%	0%	0%	-	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-414K	-2.66M	-1.62M	32.05M	0	-39.69M	0	0	0	0
Cash from Financing+	83.09M	66.95M	116.24M	96.56M	88.97M	231.72M	133.73M	14.6M	-25.21M	49.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	130K	124K	1.31M	647K	560K	1.23M	0	40.07M	1K	385K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-52.82M	55.24M	-57.78M	-99.1M	-264.1M	-110.7M	-253.02M	-73.27M	-23.38M	-40.69M
FCF Margin %	-	35.99%	-0.32%	-0.48%	-0.79%	-0.38%	-1.2%	-0.25%	-0.12%	-0.25%
FCF Growth %	-0.91%	2.05%	-2.05%	-0.72%	-1.66%	0.58%	-1.29%	0.71%	0.68%	-0.74%
FCF per Share	-2.00	1.46	-1.33	-0.85	-2.23	-0.80	-1.52	-0.40	-0.12	-0.19
FCF Conversion (FCF/Net Income)	0.86x	-0.43x	0.73x	0.57x	0.92x	0.29x	0.90x	0.78x	0.45x	0.59x
Interest Paid	0	0	0	0	781K	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-51.66%	-136.35%	-82.06%	-45.52%	-54.27%	-119.82%	-175.37%	-237.83%	-	-
Return on Invested Capital (ROIC)	-60.49%	-	-121.89%	-44.87%	-47.63%	-113.31%	-193.48%	-161.98%	-153.44%	-63.97%
Gross Margin	-	-7443%	99.65%	96.3%	56.62%	78.29%	61.5%	92.31%	61.9%	60.56%
Net Margin	-	-8843.45%	-43.21%	-82.75%	-83.48%	-130.61%	-133.25%	-32.22%	-26.68%	-43.33%
Debt / Equity	0.00x	-	-	0.02x	0.27x	0.51x	1.84x	19.08x	-	-
Interest Coverage	-120.61x	-	-	-	-204.49x	-42.59x	-13.27x	-5.15x	-7.67x	-2.78x
FCF Conversion	0.86x	-0.43x	0.73x	0.57x	0.92x	0.29x	0.90x	0.78x	0.45x	0.59x
Revenue Growth	-	-	11495.05%	16.72%	61.26%	-12.05%	-28.17%	38.19%	-33.46%	-17.7%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	-	111.12M	128.9M	142.22M	177.07M	170.3M	152.18M
Product Growth	-	-	16.00%	10.33%	24.51%	-3.82%	-10.64%
License Collaboration And Other Revenue	200.47M	223.88M	166.41M	-	-	24.32M	8M
License Collaboration And Other Revenue Growth	-	11.68%	-25.67%	-	-	-	-67.11%

Frequently Asked Questions

Growth & Financials

Akebia Therapeutics, Inc. (AKBA) reported $225.1M in revenue for fiscal year 2024.

Akebia Therapeutics, Inc. (AKBA) saw revenue decline by 17.7% over the past year.

Akebia Therapeutics, Inc. (AKBA) reported a net loss of $15.9M for fiscal year 2024.

Dividend & Returns

Akebia Therapeutics, Inc. (AKBA) generated $32.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Akebia Therapeutics, Inc. (AKBA) 10-Year Financial Performance & Capital Metrics

AKBA • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

Revenue $160M -17.7%
EBITDA -$13M -50.3%
Net Income -$69M -33.7%
EPS (Diluted) -0.33 -17.9%
Gross Margin 60.56% -2.2%
EBITDA Margin -8.1% -82.6%
Operating Margin -31.51% -32.6%
Net Margin -43.33% -62.4%
ROE -
ROIC -63.97% +58.3%
Debt/Equity -
Interest Coverage -2.78 +63.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Sales declining 13.7% over 5 years
✗Shares diluted 12.5% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-13.72%

3Y-8.87%

TTM32.49%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM65.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM67.67%

ROCE

10Y Avg-50.01%

5Y Avg-48.13%

3Y Avg-31.2%

Latest-35.85%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	1.53M	177.98M	207.74M	335M	294.64M	211.65M	292.48M	194.62M	160.18M
Revenue Growth %	-	-	114.95%	0.17%	0.61%	-0.12%	-0.28%	0.38%	-0.33%	-0.18%
Cost of Goods Sold+	96K	115.78M	617K	7.68M	145.34M	63.96M	81.49M	22.5M	74.15M	63.18M
COGS % of Revenue	-	75.43%	0%	0.04%	0.43%	0.22%	0.39%	0.08%	0.38%	0.39%
Gross Profit+	-96K	-114.25M	177.37M	200.06M	189.66M	230.68M	130.16M	269.99M	120.47M	97M
Gross Margin %	-	-74.43%	1%	0.96%	0.57%	0.78%	0.61%	0.92%	0.62%	0.61%
Gross Profit Growth %	1%	-1189.1%	2.55%	0.13%	-0.05%	0.22%	-0.44%	1.07%	-0.55%	-0.19%
Operating Expenses+	61.51M	138M	257.9M	378.2M	475.95M	608.51M	394.66M	350.77M	166.73M	147.47M
OpEx % of Revenue	-	89.9%	1.45%	1.82%	1.42%	2.07%	1.86%	1.2%	0.86%	0.92%
Selling, General & Admin	18.5M	22.21M	27.01M	87.06M	149.46M	154.1M	174.14M	138.6M	100.23M	106.55M
SG&A % of Revenue	-	14.47%	0.15%	0.42%	0.45%	0.52%	0.82%	0.47%	0.52%	0.67%
Research & Development	43.02M	115.78M	230.89M	291.07M	322.97M	218.49M	147.85M	165.99M	63.08M	37.65M
R&D % of Revenue	-	75.43%	1.3%	1.4%	0.96%	0.74%	0.7%	0.57%	0.32%	0.24%
Other Operating Expenses	287K	-188K	204K	0	3.53M	235.92M	72.67M	46.18M	3.42M	3.28M
Operating Income+	-61.51M	-136.46M	-79.92M	-178.14M	-286.29M	-377.83M	-264.5M	-80.78M	-46.26M	-50.47M
Operating Margin %	-	-88.9%	-0.45%	-0.86%	-0.85%	-1.28%	-1.25%	-0.28%	-0.24%	-0.32%
Operating Income Growth %	-0.62%	-1.22%	0.41%	-1.23%	-0.61%	-0.32%	0.3%	0.69%	0.43%	-0.09%
EBITDA+	-61.42M	-136.16M	-79.3M	-175.72M	-249.87M	-343.13M	-226.53M	-43.08M	-8.63M	-12.97M
EBITDA Margin %	-	-88.71%	-0.45%	-0.85%	-0.75%	-1.16%	-1.07%	-0.15%	-0.04%	-0.08%
EBITDA Growth %	-0.62%	-1.22%	0.42%	-1.22%	-0.42%	-0.37%	0.34%	0.81%	0.8%	-0.5%
D&A (Non-Cash Add-back)	96K	296K	617K	2.42M	36.42M	34.69M	37.97M	37.7M	37.63M	37.5M
EBIT	-61.51M	-136.46M	-76.67M	-178.16M	-286.29M	-174.52M	-227.88M	-34.64M	-45.89M	-51.23M
Net Interest Income+	0	901K	2.8M	6.15M	792K	-8.87M	-19.94M	-15.69M	-6.03M	-18.18M
Interest Income	0	901K	2.8M	6.15M	2.19M	0	0	0	0	0
Interest Expense	510K	0	0	0	1.4M	8.87M	19.94M	15.69M	6.03M	18.18M
Other Income/Expense	497K	713K	3M	6.24M	-2K	-7.01M	-17.52M	-13.45M	-5.67M	-18.94M
Pretax Income+	-60.72M	-135.75M	-76.91M	-171.9M	-286.29M	-384.84M	-282.02M	-94.23M	-51.92M	-69.41M
Pretax Margin %	-	-88.43%	-0.43%	-0.83%	-0.85%	-1.31%	-1.33%	-0.32%	-0.27%	-0.43%
Income Tax+	-510K	-901K	-2.8M	-28.34M	-6.63M	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.98%	1%	1%	1%	1%	1%
Net Income+	-60.72M	-135.75M	-76.91M	-171.9M	-279.66M	-384.84M	-282.02M	-94.23M	-51.92M	-69.41M
Net Margin %	-	-88.43%	-0.43%	-0.83%	-0.83%	-1.31%	-1.33%	-0.32%	-0.27%	-0.43%
Net Income Growth %	-0.64%	-1.24%	0.43%	-1.24%	-0.63%	-0.38%	0.27%	0.67%	0.45%	-0.34%
Net Income (Continuing)	-60.72M	-135.75M	-73.67M	-143.59M	-279.66M	-384.84M	-282.02M	-94.23M	-51.92M	-69.41M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.29	-3.60	-1.77	-1.47	-2.36	-2.53	-1.48	-0.58	-0.28	-0.33
EPS Growth %	0.05%	-0.57%	0.51%	0.17%	-0.61%	-0.07%	0.42%	0.61%	0.52%	-0.18%
EPS (Basic)	-2.29	-3.60	-1.77	-1.47	-2.36	-2.53	-1.48	-0.58	-0.28	-0.33
Diluted Shares Outstanding	26.47M	37.72M	43.5M	116.89M	118.4M	138.46M	165.95M	182.78M	187.47M	210.95M
Basic Shares Outstanding	26.47M	37.72M	43.5M	116.89M	118.4M	138.46M	165.95M	182.78M	187.47M	210.95M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	141.02M	296.32M	358.36M	468.27M	309.53M	371.44M	271.15M	185.18M	118.15M	113.83M
Cash & Short-Term Investments	138.45M	260.34M	317.79M	321.64M	147.96M	269.08M	149.8M	90.47M	42.92M	51.87M
Cash Only	49.78M	187.34M	70.16M	104.64M	147.71M	229.09M	149.8M	90.47M	42.92M	51.87M
Short-Term Investments	88.68M	73.01M	247.64M	217M	245K	39.99M	0	0	0	0
Accounts Receivable	0	33.82M	34.22M	16.67M	38.86M	28.57M	51.58M	40.28M	39.29M	34.37M
Days Sales Outstanding	-	8.04K	70.17	29.28	42.34	35.4	88.95	50.27	73.69	78.31
Inventory	0	0	0	114.25M	116.35M	61.02M	36.63M	21.57M	15.69M	16.24M
Days Inventory Outstanding	-	-	-	5.43K	292.2	348.19	164.05	349.94	77.24	93.84
Other Current Assets	2.56M	0	6.35M	15.72M	6.36M	12.76M	0	32.86M	20.24M	7.32M
Total Non-Current Assets+	1.92M	3.9M	5.89M	528.26M	461.67M	272.7M	258.2M	170.87M	123.55M	106.84M
Property, Plant & Equipment	540K	2.61M	3.62M	8.02M	39.42M	35.5M	40.61M	34.37M	16.05M	10.42M
Fixed Asset Turnover	-	0.59x	49.21x	25.89x	8.50x	8.30x	5.21x	8.51x	12.13x	15.38x
Goodwill	0	0	0	55.05M	55.05M	55.05M	59.04M	59.04M	59.04M	59.04M
Intangible Assets	0	0	0	328.15M	291.21M	144.17M	108.13M	72.08M	36.04M	0
Long-Term Investments	0	0	1.28M	2.46M	2.09M	2.04M	0	0	0	0
Other Non-Current Assets	1.38M	1.28M	2.27M	21.8M	73.89M	35.94M	50.42M	5.37M	12.42M	37.38M
Total Assets+	142.94M	300.22M	364.25M	996.54M	771.2M	644.14M	529.35M	356.05M	241.7M	220.67M
Asset Turnover	-	0.01x	0.49x	0.21x	0.43x	0.46x	0.40x	0.82x	0.81x	0.73x
Asset Growth %	0.29%	1.1%	0.21%	1.74%	-0.23%	-0.16%	-0.18%	-0.33%	-0.32%	-0.09%
Total Current Liabilities+	11.87M	114.27M	144.35M	265.69M	208.12M	187.15M	261.05M	129.54M	99.87M	80.91M
Accounts Payable	2.31M	2.04M	7M	42.8M	39.22M	41.31M	33.59M	18.02M	14.63M	15.18M
Days Payables Outstanding	8.79K	6.43	4.14K	2.03K	98.49	235.72	150.44	292.39	72.04	87.7
Short-Term Debt	0	0	0	15M	4.99M	5.29M	97.54M	32M	19.55M	4.31M
Deferred Revenue (Current)	-8K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0	0
Other Current Liabilities	6.55M	29K	46.47M	26.82M	80.93M	72.89M	31.18M	52.53M	18.26M	22.75M
Current Ratio	11.88x	2.59x	2.48x	1.76x	1.49x	1.98x	1.04x	1.43x	1.18x	1.41x
Quick Ratio	11.88x	2.59x	2.48x	1.33x	0.93x	1.66x	0.90x	1.26x	1.03x	1.21x
Cash Conversion Cycle	-	-	-	3.42K	236.06	147.87	102.57	107.82	78.88	84.46
Total Non-Current Liabilities+	74K	117.83M	100.57M	94.92M	168.33M	209.38M	194.29M	221.29M	172.42M	188.94M
Long-Term Debt	0	0	0	0	75.81M	96.38M	0	34.08M	71.2M	175.47M
Capital Lease Obligations	0	0	0	0	27.53M	24.62M	33.7M	28.96M	8.95M	3.55M
Deferred Tax Liabilities	0	0	181K	6.63M	0	0	0	0	0	0
Other Non-Current Liabilities	74K	2.51M	2.61M	32.58M	31.87M	63.03M	139.11M	114.95M	48.98M	9.93M
Total Liabilities	11.94M	232.1M	244.92M	360.61M	376.44M	396.52M	455.34M	350.82M	272.29M	269.86M
Total Debt+	14K	0	0	15M	108.32M	126.28M	136.05M	99.78M	104.18M	188.73M
Net Debt	-49.76M	-187.34M	-70.16M	-89.64M	-39.39M	-102.81M	-13.75M	9.32M	61.26M	136.86M
Debt / Equity	0.00x	-	-	0.02x	0.27x	0.51x	1.84x	19.08x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-120.61x	-	-	-	-204.49x	-42.59x	-13.27x	-5.15x	-7.67x	-2.78x
Total Equity+	131M	68.12M	119.33M	635.93M	394.76M	247.62M	74.01M	5.23M	-30.58M	-49.19M
Equity Growth %	0.26%	-0.48%	0.75%	4.33%	-0.38%	-0.37%	-0.7%	-0.93%	-6.85%	-0.61%
Book Value per Share	4.95	1.81	2.74	5.44	3.33	1.79	0.45	0.03	-0.16	-0.23
Total Shareholders' Equity	131M	68.12M	119.33M	635.93M	394.76M	247.62M	74.01M	5.23M	-30.58M	-49.19M
Common Stock	0	0	0	1K	1K	1K	1K	2K	2K	2K
Retained Earnings	-161.39M	-297.14M	-374.05M	-514.39M	-794.05M	-1.18B	-1.46B	-1.56B	-1.61B	-1.68B
Treasury Stock	-162K	0	0	0	0	0	0	0	0	0
Accumulated OCI	-234K	-42K	-442K	-261K	0	13K	6K	6K	6K	6K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-52.41M	57.91M	-56.16M	-97.49M	-257.44M	-110.39M	-252.97M	-73.15M	-23.38M	-40.66M
Operating CF Margin %	-	37.72%	-0.32%	-0.47%	-0.77%	-0.37%	-1.2%	-0.25%	-0.12%	-0.25%
Operating CF Growth %	-0.91%	2.1%	-1.97%	-0.74%	-1.64%	0.57%	-1.29%	0.71%	0.68%	-0.74%
Net Income	-60.72M	-135.75M	-76.91M	-143.59M	-279.66M	-383.46M	-282.02M	-92.56M	-51.92M	-69.41M
Depreciation & Amortization	96K	296K	617K	2.42M	38.65M	33.59M	36.13M	37.7M	41.85M	37.5M
Stock-Based Compensation	4.71M	5.83M	8.87M	19.04M	11.93M	24.46M	0	17.85M	9.32M	7.78M
Deferred Taxes	0	0	0	-28.34M	-6.63M	204.08M	0	0	0	0
Other Non-Cash Items	558K	800K	4.02M	16.95M	77.35M	24.61M	98.54M	-34.7M	-1.9M	23.15M
Working Capital Changes	2.94M	186.73M	7.25M	36.02M	-99.07M	-13.67M	-105.61M	-1.44M	-20.73M	-39.68M
Change in Receivables	0	-33.82M	-393K	33.38M	-22.2M	12.01M	-24.03M	11.7M	994K	4.05M
Change in Inventory	0	0	16.79M	26K	-29.14M	6.16M	-24.95M	19.79M	-2.54M	-28.4M
Change in Payables	231K	-274K	4.96M	13.72M	1.37M	3.68M	-11.73M	1.5M	-5.24M	-1.36M
Cash from Investing+	-13.69M	12.71M	-177.26M	36.59M	211.18M	-40M	39.94M	-114K	0	-33K
Capital Expenditures	-414K	-2.66M	-1.62M	-1.61M	-6.66M	-317K	-59K	-114K	0	-33K
CapEx % of Revenue	-	1.73%	0.01%	0.01%	0.02%	0%	0%	0%	-	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-414K	-2.66M	-1.62M	32.05M	0	-39.69M	0	0	0	0
Cash from Financing+	83.09M	66.95M	116.24M	96.56M	88.97M	231.72M	133.73M	14.6M	-25.21M	49.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	130K	124K	1.31M	647K	560K	1.23M	0	40.07M	1K	385K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-52.82M	55.24M	-57.78M	-99.1M	-264.1M	-110.7M	-253.02M	-73.27M	-23.38M	-40.69M
FCF Margin %	-	35.99%	-0.32%	-0.48%	-0.79%	-0.38%	-1.2%	-0.25%	-0.12%	-0.25%
FCF Growth %	-0.91%	2.05%	-2.05%	-0.72%	-1.66%	0.58%	-1.29%	0.71%	0.68%	-0.74%
FCF per Share	-2.00	1.46	-1.33	-0.85	-2.23	-0.80	-1.52	-0.40	-0.12	-0.19
FCF Conversion (FCF/Net Income)	0.86x	-0.43x	0.73x	0.57x	0.92x	0.29x	0.90x	0.78x	0.45x	0.59x
Interest Paid	0	0	0	0	781K	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-51.66%	-136.35%	-82.06%	-45.52%	-54.27%	-119.82%	-175.37%	-237.83%	-	-
Return on Invested Capital (ROIC)	-60.49%	-	-121.89%	-44.87%	-47.63%	-113.31%	-193.48%	-161.98%	-153.44%	-63.97%
Gross Margin	-	-7443%	99.65%	96.3%	56.62%	78.29%	61.5%	92.31%	61.9%	60.56%
Net Margin	-	-8843.45%	-43.21%	-82.75%	-83.48%	-130.61%	-133.25%	-32.22%	-26.68%	-43.33%
Debt / Equity	0.00x	-	-	0.02x	0.27x	0.51x	1.84x	19.08x	-	-
Interest Coverage	-120.61x	-	-	-	-204.49x	-42.59x	-13.27x	-5.15x	-7.67x	-2.78x
FCF Conversion	0.86x	-0.43x	0.73x	0.57x	0.92x	0.29x	0.90x	0.78x	0.45x	0.59x
Revenue Growth	-	-	11495.05%	16.72%	61.26%	-12.05%	-28.17%	38.19%	-33.46%	-17.7%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	-	111.12M	128.9M	142.22M	177.07M	170.3M	152.18M
Product Growth	-	-	16.00%	10.33%	24.51%	-3.82%	-10.64%
License Collaboration And Other Revenue	200.47M	223.88M	166.41M	-	-	24.32M	8M
License Collaboration And Other Revenue Growth	-	11.68%	-25.67%	-	-	-	-67.11%

Frequently Asked Questions

Growth & Financials

Akebia Therapeutics, Inc. (AKBA) reported $225.1M in revenue for fiscal year 2024.

Akebia Therapeutics, Inc. (AKBA) saw revenue decline by 17.7% over the past year.

Akebia Therapeutics, Inc. (AKBA) reported a net loss of $15.9M for fiscal year 2024.

Dividend & Returns

Akebia Therapeutics, Inc. (AKBA) generated $32.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.